BRPI0921868A2 - inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica - Google Patents

inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica

Info

Publication number
BRPI0921868A2
BRPI0921868A2 BRPI0921868A BRPI0921868A BRPI0921868A2 BR PI0921868 A2 BRPI0921868 A2 BR PI0921868A2 BR PI0921868 A BRPI0921868 A BR PI0921868A BR PI0921868 A BRPI0921868 A BR PI0921868A BR PI0921868 A2 BRPI0921868 A2 BR PI0921868A2
Authority
BR
Brazil
Prior art keywords
iii
inhibitors
treatment
hypertrophic cardiomyopathy
phosphodiesterase type
Prior art date
Application number
BRPI0921868A
Other languages
English (en)
Inventor
Juergen Daemmgen
Olaf Joens
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40491062&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0921868(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of BRPI0921868A2 publication Critical patent/BRPI0921868A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0921868A 2008-11-25 2009-11-23 inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica BRPI0921868A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08169897 2008-11-25
PCT/EP2009/065618 WO2010060874A1 (en) 2008-11-25 2009-11-23 Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy

Publications (1)

Publication Number Publication Date
BRPI0921868A2 true BRPI0921868A2 (pt) 2015-12-29

Family

ID=40491062

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921868A BRPI0921868A2 (pt) 2008-11-25 2009-11-23 inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica

Country Status (24)

Country Link
US (1) US8664252B2 (pt)
EP (3) EP2370070B9 (pt)
JP (1) JP5643213B2 (pt)
KR (1) KR20110089851A (pt)
CN (1) CN102223882B (pt)
AR (1) AR074214A1 (pt)
AU (1) AU2009319076A1 (pt)
BR (1) BRPI0921868A2 (pt)
CA (1) CA2744505A1 (pt)
CL (1) CL2011001026A1 (pt)
CO (1) CO6400188A2 (pt)
CY (1) CY1114791T1 (pt)
DK (1) DK2370070T3 (pt)
ES (1) ES2436716T3 (pt)
HR (1) HRP20131150T1 (pt)
MX (1) MX2011005444A (pt)
NZ (1) NZ592927A (pt)
PL (1) PL2370070T3 (pt)
PT (1) PT2370070E (pt)
SG (1) SG171783A1 (pt)
SI (1) SI2370070T1 (pt)
TW (1) TW201026684A (pt)
WO (1) WO2010060874A1 (pt)
ZA (1) ZA201103108B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) * 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
JP6272475B2 (ja) 2013-07-19 2018-01-31 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物
EA034054B1 (ru) 2013-12-04 2019-12-23 Бёрингер Ингельхайм Ветмедика Гмбх Улучшенные фармацевтические композиции пимобендана
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
WO2022073954A1 (en) 2020-10-08 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan in the anaesthesia of non-human mammals

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES482789A0 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
DE3237575A1 (de) 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8400863D0 (en) 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
DE3677316D1 (de) 1985-10-17 1991-03-07 Smith Kline French Lab 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl-derivate.
US4868182A (en) 1986-11-05 1989-09-19 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
DE3728244A1 (de) 1987-08-25 1989-03-09 Thomae Gmbh Dr K Neue (-)-benzimidazole, deren herstellung und diese verbindungen enthaltende arzneimittel
EP0306846A3 (de) 1987-09-11 1990-05-02 Dr. Karl Thomae GmbH Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Thromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
DE3804490A1 (de) 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
DE68906942T3 (de) 1988-03-29 1999-05-12 Univ Florida Pharmazeutische Zusammensetzungen für die parenterale Anwendung.
GB8824458D0 (en) 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
US5364646A (en) 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
DE4001622A1 (de) 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
WO2001097861A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
IL153705A0 (en) 2000-06-27 2003-07-06 Vectura Ltd Method of making particles for use in a pharmaceutical composition
CA2438272A1 (en) 2001-03-02 2002-10-10 John Macor Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US20030158133A1 (en) 2001-08-01 2003-08-21 Movsesian Matthew A. Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US20040037869A1 (en) 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
KR20050070036A (ko) 2002-10-07 2005-07-05 아티젼 쎄라퓨틱스, 인크. Ｌ형 칼슘 채널을 차단하는 동시에 3형포스포디에스테라제의 활성을 억제할 수 있는디히드로피리딘 화합물
CA2506741A1 (en) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure
MXPA05006975A (es) 2002-12-23 2005-12-14 Artesian Therapeutics Inc Compuestos cardiotonicos con actividad inhibidora en contra de receptores beta-adrenergicos y fosfodiesterasa.
WO2005035505A2 (en) * 2003-09-30 2005-04-21 Artesian Therapeutics, Inc. Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
JP2005281283A (ja) 2004-03-31 2005-10-13 Akira Matsumori ベンズイミダゾール系薬剤の併用医薬
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
NZ534939A (en) 2004-08-26 2007-04-27 Bomac Research Ltd Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
JP2008521806A (ja) * 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド 心不全を治療するための混合型のＰＤＥ−阻害活性およびβ−アドレナリン作用性アンタゴニスト活性または部分アゴニスト活性を有する化合物
WO2006060122A2 (en) 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
CN1702243A (zh) 2005-05-31 2005-11-30 刘坚雄 无壁板框架结构装配组合式房屋建筑及其建造方法
ES2631879T3 (es) 2005-11-14 2017-09-05 Boehringer Ingelheim Vetmedica Gmbh Uso de pimobendano para el tratamiento de la insuficiencia cardíaca asintomática (oculta)
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin

Also Published As

Publication number Publication date
EP2370070A1 (en) 2011-10-05
PT2370070E (pt) 2013-11-18
TW201026684A (en) 2010-07-16
US20110251208A1 (en) 2011-10-13
NZ592927A (en) 2013-07-26
CO6400188A2 (es) 2012-03-15
EP2370070B9 (en) 2014-04-23
EP2370070B1 (en) 2013-09-04
CN102223882B (zh) 2016-02-03
CN102223882A (zh) 2011-10-19
CA2744505A1 (en) 2010-06-03
ES2436716T3 (es) 2014-01-03
AR074214A1 (es) 2010-12-29
PL2370070T3 (pl) 2014-02-28
US8664252B2 (en) 2014-03-04
JP5643213B2 (ja) 2014-12-17
WO2010060874A1 (en) 2010-06-03
DK2370070T3 (da) 2013-12-02
MX2011005444A (es) 2011-06-09
JP2012509858A (ja) 2012-04-26
ZA201103108B (en) 2014-03-26
CL2011001026A1 (es) 2011-09-02
SI2370070T1 (sl) 2013-12-31
EP2702987A1 (en) 2014-03-05
SG171783A1 (en) 2011-07-28
AU2009319076A1 (en) 2010-06-03
EP2702986A1 (en) 2014-03-05
HRP20131150T1 (hr) 2014-01-03
KR20110089851A (ko) 2011-08-09
CY1114791T1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
BRPI0921868A2 (pt) inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica
SMT201600267B (it) Inibitori di syk imidazopirazinici
CY2020014I1 (el) Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
LTC2331547I2 (lt) Pirolopirimidino junginiai, kaip CDK inhibitoriai
DK2389382T3 (da) Aminoheterocykliske forbindelser anvendt som pde9-inhibitorer
DK3354650T3 (da) Forbindelser der er nyttige som inhibitorer af ATR-kinase
DK2364308T3 (da) Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10
BRPI0716981A2 (pt) Inibidores de cinase úteis para o tratamento de doenças proliferativas
MA32938B1 (fr) Composes organiques
EA201100037A1 (ru) Органические соединения
BRPI0911764A2 (pt) inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
NO345061B1 (no) Anvendelse av DPP-IV inhibitorer
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
DK2139892T3 (da) Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
DK2162131T3 (da) Quinolin-derivativer som pi3-kinase-inhibitorer
BRPI0920276A2 (pt) várias composições para exclusão de exon dmd
DK2346321T4 (da) Sammensætning til forbedring af effektiviteten af herbicider
SV2009003373A (es) COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759
BRPI0717411A2 (pt) Uso de inibidores de iap
EA201170832A1 (ru) Пуриновые соединения
DK2114951T3 (da) Hidtil ukendte phosphodiesterase-inhibitorer
BRPI0911332A2 (pt) composições e uso de inibidores de epas1
DK2124947T3 (da) Doseringsskema for comt-inhibitorer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]